VistaGen Therapeutics
VTGN
13 hedge funds and large institutions have $7.45M invested in VistaGen Therapeutics in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
18% more funds holding
Funds holding: 11 → 13 (+2)
7% more capital invested
Capital invested by funds: $6.94M → $7.45M (+$515K)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$905K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$109K |
| 3 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$109K |
| 4 |
Goldman Sachs
New York
|
+$44.1K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$7.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$993K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$183K |
| 3 |
Parallax Volatility Advisers
San Francisco,
California
|
-$7.6K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFM
1
Sphera Funds Management
Tel Aviv,
Israel
| $2.26M | +$905K | +8,334 | +85% |
|
|
NLVP
2
New Leaf Venture Partners
New York
| $1.49M | – | – | – |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $1.45M | -$993K | -9,140 | -44% |
|
|
4
Parallax Volatility Advisers
San Francisco,
California
| $1.24M | -$7.6K | -70 | -0.7% |
|
|
NC
5
Nexthera Capital
New York
| $575K | – | – | – |
|
|
DADC
6
D.A. Davidson & Co
Great Falls,
Montana
| $126K | +$109K | +1,000 | New |
|
|
7
Geode Capital Management
Boston,
Massachusetts
| $125K | +$109K | +1,003 | New |
|
8
HighTower Advisors
Chicago,
Illinois
| $86K | – | – | – |
|
|
9
Goldman Sachs
New York
| $51K | +$44.1K | +406 | New |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| $40K | +$7.71K | +71 | +29% |
|
|
HFM
11
Hartford Financial Management
Hartford,
Connecticut
| $5K | +$652 | +6 | +16% |
|
12
UBS Group
Zurich,
Switzerland
| $3K | +$2.82K | +26 | New |
|
|
DCM
13
DAFNA Capital Management
Los Angeles,
California
| – | -$183K | -1,563 | Closed |
|
|
14
Bank of America
Charlotte,
North Carolina
| – | -$2.17K | -20 | -91% |
|
VTGN Hedge Fund Activity: Q3 2016 in Review
13 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2016, worth a combined $7.45M — up 7.4% from $6.94M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VTGN positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Sphera Funds Management, adding an estimated $905K. The largest seller was Sabby Management, cutting an estimated $993K.
- 13 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2016, up from 11 in Q2 2016.
- Funds reported $7.45M of VistaGen Therapeutics stock for Q3 2016, up 7.4% quarter-over-quarter.
- 4 funds opened new VistaGen Therapeutics positions in Q3 2016 and 2 closed out, a net change of +2 holders.
- The largest VistaGen Therapeutics buyer in Q3 2016 was Sphera Funds Management, an estimated $905K added.
- The largest VistaGen Therapeutics seller in Q3 2016 was Sabby Management, an estimated $993K sold.
Based on aggregated 13F filings for Q3 2016.